Dana-Farber nurses present research at 2025 Oncology Nursing Society Congress
Meeting Announcement
Updates every hour. Last Updated: 30-Apr-2025 06:08 ET (30-Apr-2025 10:08 GMT/UTC)
Researchers at City of Hope have identified a new molecular target for treating pancreatic cancer, reports a Gastroenterology study published today. Led by Mustafa Raoof, M.D., M.S., City of Hope assistant professor of surgery, cancer genetics and epigenetics, scientists focused on transcription-replication conflicts (TRCs), which occur when the mechanisms responsible for gene expression and genome duplication collide. The clash disrupts cells’ ability to read and copy genes, leading to replication stress, a frequent phenomenon in pancreatic cancer. The added stress causes cells to make errors copying their DNA, enabling cancer to gain a foothold and spread. Overall, the experimental approach was most effective at killing cancer cells with high replication stress, a common phenomenon that occurs when the KRAS gene goes awry.
A team of researchers from the Rice Biotech Launch Pad at Rice University has developed an implantable “cytokine factory” that safely triggers potent immune responses against hard-to-treat cancers, including metastatic melanoma, pancreatic and colorectal tumors.
Researchers from the Agency for Science, Technology and Research (A*STAR) and the National Healthcare Group (NHG) have jointly pioneered an innovative imaging technique combining Multispectral Optoacoustic Tomography (MSOT) with artificial intelligence (AI) that could significantly improve the diagnosis and treatment of basal cell carcinoma (BCC), the most common form of skin cancer worldwide.
New Australian technology is set to transform the way that gastrointestinal cancers are detected and treated with precise, minimally invasive surgery.
As many as one in 3,000 people could be carrying a faulty gene that significantly increases their risk of a punctured lung, according to new estimates from Cambridge researchers. Previous estimates had put this risk closer to one in 200,000 people. The gene in question, FLCN, is linked to a condition known as Birt-Hogg-Dubé syndrome, symptoms of which include benign skin tumours, lung cysts, and an increased risk of kidney cancer.